These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15363993)

  • 1. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
    Moriguchi A; Mihara K; Aoki T; Maeda M; Tojo N; Matsuoka N; Mutoh S
    Eur J Pharmacol; 2004 Sep; 498(1-3):179-88. PubMed ID: 15363993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
    Moriguchi A; Aoki T; Mihara K; Tojo N; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1094-101. PubMed ID: 14634048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prohemorrhagic and bleeding time activities of recombinant tissue plasminogen activator, heparin, aspirin, and a glycoprotein IIb/IIIa antagonist.
    Mihara K; Aoki T; Moriguchi A; Maeda M; Furuichi Y; Matsuoka N; Mutoh S
    J Neurotrauma; 2005 Nov; 22(11):1362-73. PubMed ID: 16305324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet effect of FK633, a platelet glycoprotein IIb/IIIa antagonist, on thrombus formation and vascular patency after thrombolysis in the injured hamster carotid artery.
    Kaida T; Matsuno H; Niwa M; Kozawa O; Miyata H; Uematsu T
    Thromb Haemost; 1997 Mar; 77(3):562-7. PubMed ID: 9066011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
    Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
    Umemura K; Nishiyama H; Kikuchi S; Kondo K; Nakashima M
    Thromb Haemost; 1996 Nov; 76(5):799-806. PubMed ID: 8950793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery.
    Kawano K; Ikeda Y; Kondo K; Umemura K
    Eur J Pharmacol; 1999 Jun; 374(3):377-85. PubMed ID: 10422782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Pharmacol Exp Ther; 1998 Aug; 286(2):670-5. PubMed ID: 9694919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB; Li YX; Zhang H; Ren ST; Wang M; Li YP; Zang WJ; Wang B
    Thromb Res; 2011 Nov; 128(5):463-9. PubMed ID: 21924458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
    Hong TT; Driscoll EM; White AJ; Sherigill A; Giboulot TA; Lucchesi BR
    J Pharmacol Exp Ther; 2003 Aug; 306(2):616-23. PubMed ID: 12734394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
    Gold HK; Yasuda T; Jang IK; Guerrero JL; Fallon JT; Leinbach RC; Collen D
    Circulation; 1991 Jun; 83(6 Suppl):IV26-40. PubMed ID: 2040069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
    Cook JJ; Glass JD; Sitko GR; Holahan MA; Stupienski RF; Wallace AA; Stump GL; Hand EL; Askew BC; Hartman GD; Gould RJ; Lynch JJ
    Circulation; 1997 Aug; 96(3):949-58. PubMed ID: 9264506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental carotid thrombosis in the guinea pig.
    Roux S; Carteaux JP; Hess P; Falivene L; Clozel JP
    Thromb Haemost; 1994 Feb; 71(2):252-6. PubMed ID: 8191408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological properties of YM-57029, a novel platelet glycoprotein IIb/IIIa antagonist.
    Moritani Y; Sato K; Shigenaga T; Hisamichi N; Ichihara M; Akamatsu S; Suzuki Ki; Nii T; Kaku S; Kawasaki T; Matsumoto Y; Inagaki O; Tomioka K; Yanagisawa I
    Eur J Pharmacol; 2002 Mar; 439(1-3):43-52. PubMed ID: 11937091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.